Clinical Trials
57 trialsA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Morpheus Lung
Hoffmann-La Roche
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
swalloWTail
Janssen Research & Development, LLC
MTAPESTRY 101
Amgen
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Akeso
PULMO-01
iOnctura
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
KYANITE-1
Krystal Biotech, Inc.
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Dizal Pharmaceuticals
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
PRESERVE-001
OncoC4, Inc.
SPRINT
Karyopharm Therapeutics Inc
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Acclaim-2
Genprex, Inc.
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
AK104IIT018
Shanghai Chest Hospital
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
CheckMate 79X
Bristol-Myers Squibb
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
The First Affiliated Hospital of Guangzhou Medical University
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
CheckMate370
Bristol-Myers Squibb
ACWDVDFPTAN
Sir Run Run Shaw Hospital
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
M14AFS
The Netherlands Cancer Institute
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Study of PX-866 and Docetaxel in Solid Tumors
Seagen Inc.
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
SciClone Pharmaceuticals
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Takeda
An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Yonsei University
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
University of Alabama at Birmingham
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
Duke University
Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer
University of Southern California
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
Emory University
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
National Cancer Institute (NCI)